The Prognostic Impact of Epidermal Growth Factor Receptor (EGFR) in Patients with Acute Myeloid Leukaemia.
Autor: | Nath S; Department of Bioengineering and Technology, Gauhati University, Guwahati, 781014 Assam India., Bhattacharyya J; Department of Clinical Haematology, Gauhati Medical College and Hospital, Guwahati, India., Sarma PP; Department of Bioengineering and Technology, Gauhati University, Guwahati, 781014 Assam India., Saxena R; Department of Haematology, All India Institute of Medical Sciences, New Delhi, India., Sazawal S; Department of Haematology, All India Institute of Medical Sciences, New Delhi, India., Barman MP; Department of Statistics, Dibrugarh University, Dibrugarh, India., Saikia KK; Department of Bioengineering and Technology, Gauhati University, Guwahati, 781014 Assam India. |
---|---|
Jazyk: | angličtina |
Zdroj: | Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion [Indian J Hematol Blood Transfus] 2020 Oct; Vol. 36 (4), pp. 749-753. Date of Electronic Publication: 2020 Apr 09. |
DOI: | 10.1007/s12288-020-01274-z |
Abstrakt: | Expression of Epidermal Growth Factor Receptor ( EGFR ), an important proto-oncogene, regulates cell differentiation, proliferation, cell migration and survival in most of the cancer types. EGFR expression has been reported in Acute Myeloid Leukaemia (AML), however, many other reports nullified EGFR expression in AML. These contradictory data prompted us to reevaluate the expression of EGFR in AML and carry out a comparative survival analysis between EGFR expressing and non-expressing AML patients (Children and Acute Promyelocytic Leukaemia patients excluded). Bone marrow and/or peripheral blood samples were collected from 60 adult patients with AML with written informed consent. PCR, Real-Time Taqman gene expression assays were used for the detection of genetic alterations. Statistical analysis was conducted using SPSS software (IBM SPSS 20). In our study, EGFR expression was detected in 21 out of 60, in 35% (95% C.I. 23.45-48.48) AML patients. Overall survival was significantly shorter in patients with EGFR ( p = < 0.01), with an average survival of 18.57 months (95% C.I. 12.42-24.73 months) compared with 31.27 months (95% C.I. 28.19-34.33 months) in patients without EGFR . EGFR expression was significantly higher in female patients compared to male ( p = 0.037).This study confirms the presence of EGFR in AML and indicates that EGFR expression confers poor prognosis in AML. However, the underlying cause of this adverse prognostic effect has not been identified. Further clinical studies are warranted to determine the exact mechanism through which EGFR activity might contribute to AML progression and identify the potential therapeutic target for the reversal of resistance to conventional chemotherapeutics. Competing Interests: Conflict of interestSukanta Nath, Jina Bhattacharya, Partha Pratim Sarma, Renu Saxena, Sudha Sazawal, Manash Pratim Barman and Kandarpa Saikia declare that they have no conflict of interest. (© Indian Society of Hematology and Blood Transfusion 2020.) |
Databáze: | MEDLINE |
Externí odkaz: |